Saudi Pharmaceutical Industries and Medical Appliances – Kingdom of Saudi Arabia
The capital of SPIMACO is SAR 1,200,000,000 equivalent to KWD 93,600,000. ACDIMA owns 20.488% in SPIMACO’s capital.
SPIMACO is one the major pharmaceutical companies in the Arab World, which continues to strengthen its investments. it currently has expansion projects in its factory which are expected to be completed by the end of 2015. The company owns several companies including ARAC and contributes in many other companies, including ENAYA, TAPHCO, CAD, EirGen Pharma, IPharma and Dammam Pharma.
SPIMACO’s sales in 2014 amounted to SAR 1.47 billion, with 12.2% increase as compared to the previous year, thus achieving a profit in the same year with the amount of SAR 316.9 million, equivalent to KWD 24.7 million, with 18.75% increase as compared to the previous financial year, 2013.
Official website : http://www.spimaco.com.sa